US Pharma MarketingThe post Keenova seeks Xiaflex expansion on late-stage rare disease win appeared first on Clinical Trials Arena.
Keenova seeks Xiaflex expansion on late-stage rare disease win
If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis. If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis. Keenova plans to submit an application for Xiaflex in plantar fibromatosis in Q4 2026. Credit: Pixel-Shot / Shutterstock.com. Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a Phase III win in rare foot disease, plantar fibromatosis. To put Xiaflex to the test in this indication, Keenova conducted the pivotal EN3835-309, or STRIDE study (NCT06151197), in which the company…
If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
Source: Clinical Trials Arena